Key Points
- Karen Dawes sold 275 shares at an average price of $161 on Dec. 17 for a total of $44,275, leaving her with 91,821 shares (a 0.30% reduction in her position).
- Repligen beat Q3 expectations with $0.46 EPS (vs. $0.42 expected) and $188.81M revenue, up 21.9% year-over-year, and set FY2025 guidance of 1.650–1.680 EPS.
- The stock has an $8.88B market cap and a 12‑month range of $102.96–$182.52, with an average analyst rating of Moderate Buy and an average target price of $177.92.
Repligen Corporation (NASDAQ:RGEN - Get Free Report) Director Karen Dawes sold 275 shares of the business's stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $161.00, for a total value of $44,275.00. Following the sale, the director directly owned 91,821 shares of the company's stock, valued at approximately $14,783,181. This trade represents a 0.30% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
Repligen Stock Performance
Repligen stock opened at $157.72 on Friday. The company has a market cap of $8.88 billion, a price-to-earnings ratio of 7,889.94, a price-to-earnings-growth ratio of 3.53 and a beta of 1.11. Repligen Corporation has a 12 month low of $102.96 and a 12 month high of $182.52. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.36 and a quick ratio of 7.14. The stock's 50-day moving average is $156.75 and its 200-day moving average is $135.54.
Repligen (NASDAQ:RGEN - Get Free Report) last issued its earnings results on Tuesday, October 28th. The biotechnology company reported $0.46 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.42 by $0.04. Repligen had a return on equity of 4.66% and a net margin of 0.25%.The business had revenue of $188.81 million during the quarter, compared to analysts' expectations of $181.23 million. During the same quarter in the previous year, the business earned $0.43 EPS. The company's revenue for the quarter was up 21.9% on a year-over-year basis. Repligen has set its FY 2025 guidance at 1.650-1.680 EPS. Equities analysts anticipate that Repligen Corporation will post 1.72 earnings per share for the current year.
Wall Street Analyst Weigh In
Several equities research analysts have recently issued reports on the stock. Royal Bank Of Canada reissued an "outperform" rating and issued a $205.00 price objective on shares of Repligen in a research report on Tuesday, September 2nd. HC Wainwright restated a "buy" rating and set a $180.00 price objective on shares of Repligen in a research note on Wednesday, September 3rd. Canaccord Genuity Group increased their target price on Repligen from $150.00 to $165.00 and gave the company a "hold" rating in a research note on Wednesday, October 29th. Jefferies Financial Group set a $160.00 price target on Repligen and gave the stock a "hold" rating in a research report on Tuesday, October 28th. Finally, HSBC initiated coverage on shares of Repligen in a research note on Wednesday, October 1st. They set a "buy" rating and a $150.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $177.92.
Check Out Our Latest Stock Report on RGEN
Hedge Funds Weigh In On Repligen
Several institutional investors and hedge funds have recently made changes to their positions in the business. Hudson Bay Capital Management LP acquired a new stake in shares of Repligen during the third quarter worth approximately $2,807,000. Swiss Life Asset Management Ltd acquired a new stake in Repligen in the third quarter valued at $331,000. CIBC Bancorp USA Inc. bought a new position in Repligen during the 3rd quarter valued at $485,000. Wilmington Savings Fund Society FSB boosted its stake in Repligen by 2,750.0% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 513 shares of the biotechnology company's stock valued at $69,000 after acquiring an additional 495 shares during the last quarter. Finally, Danske Bank A S acquired a new position in Repligen during the 3rd quarter worth $107,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.
About Repligen
(
Get Free Report)
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
